NCT03519464
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
StatusCompleted
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 359 versions: 7 with changes below, 43 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Primary completion date changed from estimate of Dec 31, 2026 to Mar 6, 2026
- New version filed on ClinicalTrials.gov
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 100 to confirmed 54
- Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v341
- Minor Secondary endpoints: details revised at 2 of 2 entriesv336
Show 2 earlier versionsHide 2 earlier versions
- Notable Primary and study completion dates: Feb 28, 2024 to Dec 31, 2025v335
- Notable Primary and study completion dates: Feb 28, 2023 to Feb 28, 2024v331
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients with ICL who become seropositive to at least 1 homologous HPV vaccine genotype at 1 month after completion of the vaccination schedule.
Timeframe: 1 month (+ 1 month) after vaccination #3.
Secondary (2)
Humoral responses, expressed as geometric mean titer (GMT), will be compared between patients with ICL and healthy subjects, within the subgroup of subjects who seroconvert for any specific homologous HPV genotype.
Number of adverse events (AEs) and serious adverse events (SAEs) following administration of 9-valent HPV recombinant vaccine.
Arms and interventions
ICL and Healthy VolunteersOther
Biological/Vaccine
Biologicals: Gardasil 9
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States